• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by CVRx Inc.

    5/23/25 4:15:19 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    SD 1 tm2515710d1_sd.htm FORM SD

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM SD

     

    Specialized Disclosure Report

     

    CVRx, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or other jurisdiction
    of incorporation)
    001-40545
    (Commission
    File Number)
    41-1983744
    (I.R.S. Employer
    Identification No.)

     

    9201 West Broadway Avenue, Suite 650

    Minneapolis, MN

    (Address of principal executive offices)

     

    55445

    (Zip code)

     

    Jared Oasheim

    Chief Financial Officer

    (763) 416-2840

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

     

    x  Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ¨ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ___.

     

     

     

     

     

     

    Section 1 – Conflict Minerals Disclosure

     

    Items 1.01 and 1.02 Conflict Minerals Disclosure and Report, Exhibit

     

    Conflict Minerals Disclosure

     

    As required by Rule 13p-1 (the “Rule”), CVRx, Inc. (the “Company”) identified that certain components of the Company’s Barostim device that entered the stream of commerce in the calendar year ended December 31, 2024 were potentially in the scope of the Rule for the year ended December 31, 2024.

     

    These components were provided to the Company by a number of contract manufacturers and distributors. The Company conducted a reasonable country of origin inquiry (“RCOI”) for the year ended December 31, 2024 but was unable to obtain documentation from some of the relevant suppliers on whether these components contain tin, tungsten, tantalum or gold (the “3TG Minerals”), or if relevant, about the country of origin of any 3TG Minerals incorporated into the products. As a result, the Company cannot rule out the possibility that these products contained 3TG Minerals originating in the Democratic Republic of the Congo or an adjoining country (collectively, the “Covered Countries”).

     

    Generally speaking, the amount of information available globally on the traceability and sourcing of these ores is limited at this time. The Company asked its suppliers to provide answers to the Supply Chain Questionnaire adapted from the Conflict Minerals Reporting Template (“CMRT”) developed by the Responsible Minerals Initiative reflecting the Company’s position on the supply chain. The Company reviewed the questionnaires received for completeness and consistency of answers and asked for corrections and clarifications where needed. As such, the Company believes the RCOI process that it followed was performed in good faith and reasonably designed to determine whether any of the 3TG metals originated in any Covered Country or are from recycled or scrap sources. However, there are inherent limitations in the information provided by third parties including, but not limited to, potential inaccuracies, incompleteness or falsified information despite the Company’s efforts to validate and confirm the information.

     

    The information in this Form SD is publicly available on the Company’s website at https://ir.cvrx.com/financial-information/sec-filings; however, the information on the Company’s website is not incorporated by reference into this Form SD and does not constitute a part of this Form SD.

     

    Pursuant to the Public Statement issued by the SEC’s Division of Corporate Finance on April 7, 2017, the Company has provided only the disclosure required under the provisions of paragraphs (a) and (b) of Item 1.01 of Form SD.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

      CVRX, INC.
      (Registrant)
       
      By: /s/ Jared Oasheim
      Name: Jared Oasheim
      Title: Chief Financial Officer
      Date: May 23, 2025

     

     

     

    Get the next $CVRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Nielsen Kirk G.

      4 - CVRx, Inc. (0001235912) (Issuer)

      6/5/25 5:35:50 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Jain Mudit K.

      4 - CVRx, Inc. (0001235912) (Issuer)

      6/5/25 5:35:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Slattery Joseph P

      4 - CVRx, Inc. (0001235912) (Issuer)

      6/5/25 5:19:19 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Financials

    Live finance-specific insights

    See more
    • CVRx Reports First Quarter 2025 Financial and Operating Results

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

      5/8/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

      MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

      4/24/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports Preliminary First Quarter 2025 Financial Results

      MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev

      4/7/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CVRx, Inc. downgraded by Analyst with a new price target

      Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

      5/9/25 8:41:10 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx, Inc. upgraded by William Blair

      William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

      1/14/25 7:51:14 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

      Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

      9/10/24 7:46:21 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CVRX
    SEC Filings

    See more
    • CVRx to Present at the William Blair 45th Annual Growth Stock Conference

      MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical device co

      5/28/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports First Quarter 2025 Financial and Operating Results

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

      5/8/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

      MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

      4/24/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by CVRx Inc.

      SC 13D/A - CVRx, Inc. (0001235912) (Subject)

      11/7/24 9:10:51 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CVRx Inc.

      SC 13G/A - CVRx, Inc. (0001235912) (Subject)

      11/1/24 11:05:15 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

      SC 13G/A - CVRx, Inc. (0001235912) (Subject)

      2/6/24 7:56:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CVRx, Inc. (0001235912) (Filer)

      6/5/25 4:16:22 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by CVRx Inc.

      SD - CVRx, Inc. (0001235912) (Filer)

      5/23/25 4:15:19 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by CVRx Inc.

      10-Q - CVRx, Inc. (0001235912) (Filer)

      5/9/25 8:25:25 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    See more
    • CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

      MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

      6/25/24 6:50:00 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

      Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

      1/31/24 8:00:00 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

      MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

      12/20/22 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nielsen Kirk G. bought $59,795 worth of shares (10,966 units at $5.45) (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/19/25 6:46:37 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/14/25 5:27:07 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/13/25 7:12:40 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care